42 completed, 5 terminated, 2 unknown, 1 active not recruiting. 26 Phase 3, 14 Phase 1, 10 Phase 2, 1 Early Phase 1, 1 Not applicable.
Follow brivaracetam: new trials by email Literature Review of brivaracetam trials Research Report on brivaracetam
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Epileptic Hippocampus in Alzheimer's Disease Brivaracetam - Alzheimer Disease, Mild Cognitive Impairment | Phase 1 / Phase 2 | Not yet recruiting | University of California, Los Angeles | 25 | 2026-01-01 | 2026-01-27 |
| Bioequivalence Study of Two Brivaracetam Oral Solutions in Healthy Adults Under Fasting and High-Fat Meal Conditions Brivaracetam Oral Solution (Test Formulation), Brivaracetam Oral Solution (Reference Formulation) - Epilepsy (treatment Refractory) | Phase 1 | Unknown | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. | 60 | 2024-10-21 | 2025-01-08 |
| Brivaracetam Bioequivalence Assessment Briveka ® 100 mg, Briviact® 100 mg - Bioequivalence Study in Healthy Subjects | Phase 1 | Completed | Zodiac Produtos Farmaceuticos S.A. | 28 | 2024-08-09 | 2026-09-02 |
| Comparison of Oral Brivaracetam Versus Levetiracetam as Monotherapy in Epilepsy Brivaracetam, Levetiracetam - Epilepsy | Not applicable | Completed | RESnTEC, Institute of Research | 102 | 2024-08-01 | 2025-09-09 |
| A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy Brivaracetam Film-coated tablet, Brivaracetam oral solution - Childhood Absence Epilepsy, Juvenile Absence Epilepsy | Phase 3 | Active not recruiting | UCB Biopharma SRL | 70 | 2024-07-10 | 2026-08-27 |
| A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Japanese Male Study Participants brivaracetam (BRV) tablet, brivaracetam (BRV) dry syrup - Healthy Study Participants | Phase 1 | Completed | UCB Biopharma SRL | 64 | 2024-03-25 | 2025-06-06 |
| Brivaracetam to Reduce Neuropathic Pain in Chronic SCI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial brivaracetam, Placebo - Spinal Cord Injuries, Neuropathic Pain | Phase 3 | Completed | University of Minnesota | 44 | 2023-01-01 | 2026-03-18 |
| An Open Label, Balanced, Randomized, 3×3 Latin Square Design Comparing of Brivaracetam Sustained-release Tablets and Brivaracetam Tablets in the Oral Comparative Pharmacokinetic(PK) Study in Chinese Healthy Adult Subjects Under Fasting Conditions. Brivaracetam tablets (50mg/ tablet, BRIVIACT®, UCB), Brivaracetam sustained-release tablets 100mg, Brivaracetam sustained-release tablets 50mg - Partial Seizure | Phase 1 | Unknown | Overseas Pharmaceuticals, Ltd. | 12 | 2022-09-13 | 2023-02-01 |
| Tolerability and Activity of Brivaracetam (BRV) in Patients With Diffuse Gliomas Brivaracetam - Brain Tumor | Early Phase 1 | Terminated | University of Rochester | 3 | 2022-05-17 | 2026-06-03 |
| A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Male Japanese Study Participants brivaracetam - Healthy Study Participants | Phase 1 | Completed | UCB Biopharma SRL | 24 | 2022-04-04 | 2024-01-05 |
| A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy Brivaracetam Film-coated tablet, Brivaracetam oral solution - Childhood Absence Epilepsy, Juvenile Absence Epilepsy | Phase 3 | Completed | UCB Biopharma SRL | 84 | 2022-03-30 | 2025-10-22 |
| Drug Concentrations in Breast Milk and Prediction of Blood Levels of the Breastfed Infants either of Atenolol, Bupropion, Brivaracetam, Escitalopram, Fluconazole, Lacosamide, Lamotrigine, Levetiracetam, Methotrexate or Ezetimibe - Breast Feeding | Completed | The Hospital for Sick Children | 39 | 2022-03-09 | 2024-04-10 | |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy Brivaracetam, Placebo - Childhood Absence Epilepsy, Juvenile Absence Epilepsy | Phase 3 | Completed | UCB Biopharma SRL | 154 | 2021-07-29 | 2026-10-30 |
| A Study to Evaluate the Pharmacokinetics and Safety of Brivaracetam in Healthy Chinese Subjects brivaracetam - Healthy Participants | Phase 1 | Completed | UCB Biopharma SRL | 12 | 2021-05-19 | 2023-03-13 |
| A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures Brivaracetam - Epilepsy | Phase 3 | Recruiting | UCB Biopharma SRL | 70 | 2021-03-11 | 2026-07-27 |
| Long-term Safety and Efficacy of Adjunctive Brivaracetam in Chinese Patients With Uncontrolled Focal Epilepsy Brivaracetam - Epilepsy, Focal | Phase 3 | Completed | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | 141 | 2021-02-07 | 2026-05-04 |
| Brivaracetam to Reduce Neuropathic Pain in Chronic Spinal Cord Injury Brivaracetam, Placebo - Spinal Cord Injuries | Phase 1 / Phase 2 | Completed | University of Minnesota | 24 | 2021-02-01 | 2025-10-14 |
| A Study to Test the Pharmacokinetics, Efficacy, and Safety of Brivaracetam in Newborns With Repeated Electroencephalographic Seizures Brivaracetam (BRV) intravenous (iv), Brivaracetam (BRV) oral - Electroencephalographic Neonatal Seizures | Phase 3 | Terminated | UCB Biopharma SRL | 9 | 2019-05-07 | 2024-04-08 |
| A Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam (BRV) as Replacement for Oral Brivaracetam in Japanese Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization Brivaracetam - Partial Seizures With or Without Secondary Generalization, Epilepsy | Phase 3 | Completed | UCB Biopharma S.P.R.L. | 10 | 2019-01-04 | 2021-04-13 |
| Brivaracetam: a Prospective and Multicentre Post-marketing Observational Study Brivaracetam - Epilepsy | Completed | Centre hospitalier de l'Université de Montréal (CHUM) | 51 | 2018-10-04 | 2023-12-19 |
Showing 20 of 53. Sign in to see all of them.
Epilepsy (37) · Epilepsy, Absence (3) · Epilepsies, Partial (2) · Myoclonic Epilepsies, Progressive (2) · Myoclonus (2) · Spinal Cord Injuries (2) · Unverricht-Lundborg Syndrome (2) · Alzheimer Disease (1) · Brain Neoplasms (1) · Breast Feeding (1) · Cognitive Dysfunction (1) · Neuralgia (1) · Neuralgia, Postherpetic (1) · Seizures (1)
UCB Pharma (16) · UCB Biopharma SRL (11) · UCB Pharma SA (8) · UCB Biopharma S.P.R.L. (4) · UCB BIOSCIENCES, Inc. (2) · University of Minnesota (2) · Centre hospitalier de l'Université de Montréal (CHUM) (1) · Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (1) · Jiangxi Qingfeng Pharmaceutical Co. Ltd. (1) · Overseas Pharmaceuticals, Ltd. (1) · RESnTEC, Institute of Research (1) · The Hospital for Sick Children (1) · UCB PHARMA Inc. (US) (1) · University of California, Los Angeles (1) · University of Rochester (1)
United States (29) · Germany (18) · France (16) · Italy (15) · Spain (15) · Czechia (14) · Belgium (13) · Canada (10) · Poland (10) · Hungary (9) · Mexico (9) · Netherlands (9) · Japan (8) · United Kingdom (8) · Finland (7)
Ikram Rahman (1) · Keith A Vossel, MD, MSc (1) · Leslie Morse, DO (1) · Mark R Keezer, MDCM PhD (1) · Nuzhat Rahman, FCPS (1) · Philipp von Rosenstiel, M.D. (1) · Philipp von Rosenstiel, MD. (1) · Ricardo Battaglino, PhD (1) · Scott Falci, MD (1) · Zhen Hong, MD (1)
PMID 26899665, PMID 33461041, PMID 34218211, PMID 35285519, PMID 27265725, PMID 27335114, PMID 27589414, PMID 27608437, PMID 27988967, PMID 28004320, PMID 28236727, PMID 28279891, PMID 29414542, PMID 29908435, PMID 32432339, PMID 34155568, PMID 35582748, PMID 38788664, PMID 26471380, PMID 26666500, PMID 29486396, PMID 31937513, PMID 33780735, PMID 36435010, PMID 20887370, PMID 22813235, PMID 24116853, PMID 24256083, PMID 24446953, PMID 26432008, PMID 30924924, PMID 32221987, PMID 34570177, PMID 35196395, PMID 35844134, PMID 37597326, PMID 38049197, PMID 38932723, PMID 40549270, PMID 40737960, PMID 40944847, PMID 41998831
2008 (4), 2004 (3), 2023 (2), 2015 (1), 2016 (1), 2018 (1)